Safety Profile and Side Effects of CJC-1295 Safety data derive from approximately 300 trial participants, revealing dose-related reported risks
The dilemma comes amid a similar debate at the federal level
In markets like obesity, where out-of-pocket spending is growing significantly, oral and ultra long-acting options could accelerate consumerisation, challenge traditional reimbursement models and demand new approaches - not just in therapeutic innovation, but in go-to-market models
Semaglutide, the active ingredient in Ozempic, has become one of the most prescribed GLP-1 medications for weight management, with over 4 million prescriptions filled in 2023 alone
Prolonged inhibition of DPP may prevent the formation of GLP-1 (9-36) amide, and might ultimately augment oxidative stress in the heart, vasculature, and liver, and promote hepatic glucose production, which would be undesirable in the treatment of obesity-related diabetes
You can also access free resources through the National Eating Disorders Association (NEDA)
